Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $47.57.
Tarsus Pharmaceuticals (TARS) announced the appointment of Katherine Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Published first on TheFly – the ultimate ...
Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands ...
On Friday, Tarsus Pharmaceuticals Inc (TARS) stock saw a modest uptick, ending the day at $39.41 which represents a slight increase of $0.52 or 1.34% from the prior close of $38.89. The stock opened ...
TARS Project Management has shifted its focus to India’s pre-IPO market, aiming to tap into the country's private sector opportunities. The firm has received support from ADIB, a leading ...
Tarsus Pharmaceuticals TARS is set to give its latest quarterly earnings report on Wednesday, 2024-11-13. Here's what investors need to know before the announcement. Analysts estimate that Tarsus ...